FGFR3 and urothelial carcinoma: In the open-label, phase II study BLC2001 presented at the 2018 ASCO Annual Symposium [65], erdafitinib, an oral pan-FGFR tyrosine kinase inhibitor, was tested in 96 patients with metastatic or unresectable urothelial carcinoma and FGFR alterations (mutation in FGFR3 or fusion in FGFR2 or FGFR3).